Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 20.02
(-2.58%)
CNY 20.02
(-2.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 574.96 Million CNY | 5.89% |
| 2022 | 524.25 Million CNY | 3.02% |
| 2021 | 508.89 Million CNY | 22.61% |
| 2020 | 415.03 Million CNY | 13.48% |
| 2019 | 365.74 Million CNY | 38.94% |
| 2018 | 263.24 Million CNY | 35.33% |
| 2017 | 194.52 Million CNY | 8.11% |
| 2016 | 179.93 Million CNY | 22.68% |
| 2015 | 146.67 Million CNY | 78.74% |
| 2014 | 82.05 Million CNY | 59.03% |
| 2013 | 51.59 Million CNY | 67.09% |
| 2012 | 30.87 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 162.7 Million CNY | -8.83% |
| 2024 Q1 | 133.22 Million CNY | -22.22% |
| 2024 Q2 | 178.89 Million CNY | 34.28% |
| 2023 Q2 | 161.97 Million CNY | 71.03% |
| 2023 Q4 | 171.28 Million CNY | 12.22% |
| 2023 FY | 555.12 Million CNY | 5.89% |
| 2023 Q1 | 94.7 Million CNY | -40.16% |
| 2023 Q3 | 152.63 Million CNY | -5.77% |
| 2022 Q3 | 128.28 Million CNY | 3.19% |
| 2022 Q2 | 124.3 Million CNY | 9.61% |
| 2022 FY | 524.25 Million CNY | 3.02% |
| 2022 Q1 | 113.4 Million CNY | -33.23% |
| 2022 Q4 | 158.25 Million CNY | 23.36% |
| 2021 Q1 | 91.44 Million CNY | -34.74% |
| 2021 FY | 508.89 Million CNY | 22.61% |
| 2021 Q4 | 169.84 Million CNY | 30.18% |
| 2021 Q2 | 117.13 Million CNY | 28.1% |
| 2021 Q3 | 130.47 Million CNY | 11.38% |
| 2020 Q2 | 105.44 Million CNY | 94.11% |
| 2020 FY | 415.03 Million CNY | 13.48% |
| 2020 Q1 | 54.32 Million CNY | -53.3% |
| 2020 Q4 | 140.11 Million CNY | 21.68% |
| 2020 Q3 | 115.14 Million CNY | 9.2% |
| 2019 Q4 | 116.31 Million CNY | 23.6% |
| 2019 FY | 365.74 Million CNY | 38.94% |
| 2019 Q3 | 94.1 Million CNY | 9.06% |
| 2019 Q2 | 86.28 Million CNY | 25.0% |
| 2019 Q1 | 69.03 Million CNY | -15.64% |
| 2018 Q1 | 50.95 Million CNY | 0.42% |
| 2018 Q4 | 81.82 Million CNY | 16.09% |
| 2018 FY | 263.24 Million CNY | 35.33% |
| 2018 Q3 | 70.48 Million CNY | 17.52% |
| 2018 Q2 | 59.97 Million CNY | 17.7% |
| 2017 FY | 194.52 Million CNY | 8.11% |
| 2017 Q1 | 37.82 Million CNY | -32.41% |
| 2017 Q3 | 57.28 Million CNY | 17.69% |
| 2017 Q2 | 48.67 Million CNY | 28.7% |
| 2017 Q4 | 50.74 Million CNY | -11.42% |
| 2016 Q3 | 48.96 Million CNY | 46.23% |
| 2016 Q1 | 33.48 Million CNY | 0.0% |
| 2016 FY | 179.93 Million CNY | 22.68% |
| 2016 Q4 | 55.95 Million CNY | 14.28% |
| 2016 Q2 | 33.48 Million CNY | -0.0% |
| 2015 Q1 | 26.38 Million CNY | 0.0% |
| 2015 FY | 146.67 Million CNY | 78.74% |
| 2015 Q2 | 26.38 Million CNY | 0.0% |
| 2014 FY | 82.05 Million CNY | 59.03% |
| 2013 FY | 51.59 Million CNY | 67.09% |
| 2012 FY | 30.87 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 82.851% |
| Hangzhou Tigermed Consulting Co., Ltd. | 358.41 Million CNY | -60.418% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | -48.507% |
| Beijing Strong Biotechnologies, Inc. | 702.74 Million CNY | 18.183% |
| Medicalsystem Biotechnology Co., Ltd. | 562.06 Million CNY | -2.295% |
| Maccura Biotechnology Co.Ltd | 1.18 Billion CNY | 51.291% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.17 Billion CNY | 51.083% |
| Guangdong Hybribio Biotech Co.,Ltd. | 631.43 Million CNY | 8.943% |
| BGI Genomics Co., Ltd. | 1.93 Billion CNY | 70.351% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | -19.792% |